- Home
- / Caribou Biosciences
Caribou Biosciences
Stock Price
$1.9
2024-10-29
Market Capitalization
$174.4 M
2024-10-29
Revenue
$34.5 M
FY, 2023
Caribou Biosciences Summary
Company Summary
- Overview
- Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company. It develops chRDNA, a technology for complex genome editing, and CAR-T, a cell therapy platform.
- Type
- Public
- Status
- Active
- Founded
- 2012
- HQ
- Berkeley, CA, US | view all locations
- Website
- https://www.cariboubio.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Barbara McClung, Chief Legal Officer and Corporate Secretary
Jason O'Byrne, Chief Financial Officer
Caribou Biosciences Financials
Summary Financials
- Revenue (Q3, 2024)
- $2.0M
- Net income (Q3, 2024)
- ($34.7M)
- Cash (Q3, 2024)
- $32.0M
- EBIT (Q3, 2024)
- ($38.2M)
- Enterprise value
- $169.1M